Post-Polio Syndrome
Conditions
Keywords
Post-polio syndrome, IvIg
Brief summary
Inflammatory cytokines in the cerebrospinal fluid may contribute to the new muscle weakness, fatigue and pain experienced by patients with post-polio syndrome. Intravenousimmunoglobulin (IvIg) reduces this inflammation. The purpose of this study is to investigate the clinical effect of IvIg in post-polio syndrome.
Detailed description
Post-polio syndrome (PPS) is characterised by new muscle weakness, pain, and fatigue several years after the attack of acute polio. This leads to increased disability, and up to now only supportive therapy is available. Patients with PPS lose more motor neurons than expected and surviving neurons fail to maintain neurogenic supply to enlarged motor units. New data report an increased level of inflammatory cytokines in the cerebrospinal fluid (CSF). Immune modulating therapy like IvIg could be an option and this pilot study is the first to investigate the clinical effect of IvIg in PPS. In addition, levels of cytokines in CSF and serum before and after treatment will be investigated.
Interventions
DRUGIvIg
Sponsors
Haukeland University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
0 Years to 75 Months
Healthy volunteers
Yes
Inclusion criteria
Post-polio syndrome diagnosed at Dept of Neurology, Haukeland University Hospital Walking ability -
Exclusion criteria
Other autoimmune disorders Other ongoing autoimmune therapy Severe cardiopulmonary disease IgA deficiency Previous treatment of IvIg Wheelchair dependence
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain after three months | — |
| Fatigue after 3 months | — |
| Muscle strength after 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain, Fatigue, Muscle strength after 6 months. Changes in cytokine levels in CSF and serum | — |
Outcome results
None listed